A Randomized Controlled Trial Comparing Glargine U300 and Glargine U100 for the Inpatient Management of Medicine and Surgery Patients With Type 2 Diabetes: Glargine U300 Hospital Trial

Open label RCT (n=176) found no difference in mean daily blood glucose (BG), % of readings within target BG, or insulin total daily dose, though there were lower rates of clinically significant hypoglycaemia with U300 glargine vs U100 glargine (0% vs 6%, p=0.023).

Source:

Diabetes Care